<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784900</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000475-17</org_study_id>
    <secondary_id>2011/1793</secondary_id>
    <nct_id>NCT01784900</nct_id>
  </id_info>
  <brief_title>Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab</brief_title>
  <acronym>IIPOP</acronym>
  <official_title>Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment by association of complete surgical excision of the lesions and intraperitoneal
      immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>every 3 months for the first two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Patients With Gastric Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Schema B (140µg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D0 : 20 μg of catumaxomab
D2 : 40 μg
D4 : 80 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schema A (100µg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D0 : 10 μg of catumaxomab
D2 : 30 μg
D4 : 60 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab 100µg</intervention_name>
    <arm_group_label>Schema A (100µg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab 140µg</intervention_name>
    <arm_group_label>Schema B (140µg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consent form signed

          -  Age &gt;= 18

          -  Carcinomatosis pre operative known or discivered in intraoperative

          -  Patients uin good general condition who may have extent surgery associated to specific
             inflammatory syndrom of immunotherapy

          -  Patients in good general condition

          -  Patient insured to social care

        Inclusion Criteria (intraoperative):

          -  Gastric adenocarcinoma with macroscopic peritoneal carcinomatosis (PC) confirmed by
             extemporaneous histological examination

          -  CP extension minimal or moderate (peritoneal index ≤ 12).

          -  Resection of the entire macroscopic lesions detectable (primary tumor, lymph nodes and
             CP). cleaning D2 lymph node (or D1.5).

        Exclusion Criteria:

          -  Presence of metastasis in reach

          -  Previous treatment with a non-humanized monoclonal AC- (mice or rat)

          -  Hypersensitivity to any type of antibody.

          -  History of cancer within 5 years preceding the entry in the trial other than basal
             cell skin carcinoma or in situ of the cervix,

          -  Patients already included in another clinical trial with experimental molecule

          -  Pregnant, or likely to be or breastfeeding, (Women of childbearing potential should
             have a pregnancy test (blood) negative 15 days before the date of the surgery) Using
             of a suitable method of contraception for patients of childbearing age during
             treatment. adequate contraception Methods includeare: an intrauterine device, hormonal
             contraception, condom use combined with a spermicide

          -  Persons deprived of liberty or Trust (including curatorship)

          -  Unable to undergo medical test for geographical, social or psychological.

        Exclusion Criteria (intraoperative):

          -  Persistent peritoneal lesions visible to the end of the surgery

          -  Resection of the tail of the pancreas or pancreatic break (because no drainage
             post-op); break pleural (for K cardia)

          -  Presence of metastasis in reach during surgery (except for ovarian metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

